Valuation: SpringWorks Therapeutics, Inc.

Market Cap 354.06Cr 309.42Cr 285.52Cr 263.18Cr 496.04Cr 34TCr 507.06Cr 3.41TCr 1.34TCr 17TCr 1.33TCr 1.3TCr 57TCr P/E 2023
-7.09x
P/E 2024 -10.4x
Enterprise Value 308.66Cr 269.74Cr 248.91Cr 229.43Cr 432.44Cr 30TCr 442.04Cr 2.98TCr 1.17TCr 15TCr 1.16TCr 1.13TCr 50TCr EV / Sales 2023
36,25,07,725x
EV / Sales 2024 1,16,54,155x
Free-Float
97.93%
Yield 2023 *
-
Yield 2024 -
3 years 18
Extreme 18
62
5 years 13.6
Extreme 13.6
89.75
10 years 13.6
Extreme 13.6
96.48
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/01/2023
Compliance Officer - 01/01/2022
Investor Relations Contact - 01/08/2018
Date Insider Type Main position Quantity % Market Cap.
01/07/25 Issuer sale

Director

1,03,482 0.1381%
01/07/25 Issuer sale

Executive/Senior Manager

3,79,322 0.5062%
01/07/25 Issuer sale

Chief Operating Officer

8,95,788 1.1954%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%-.--%-.--%+59.56% 354.06Cr
-0.33%+1.83%+24.73%-6.86% 6.88TCr
+0.67%+0.93%+36.86%+197.49% 5.21TCr
+0.94%+39.60%+39.60%+39.60% 4.35TCr
+1.12%+0.35%-52.09%-53.39% 4.12TCr
-1.40%+3.43%+64.81%-25.41% 3.04TCr
-2.11%-9.45%+97.76%-49.58% 2.45TCr
+0.51%+0.46%+72.78%+90.09% 2.34TCr
-5.57%-0.84%-0.11%+182.38% 1.98TCr
-0.86%-1.99%+70.03%+117.01% 1.66TCr
Average -0.70%-0.72%+35.44%+55.09% 3.24TCr
Weighted average by Cap. -0.33%-0.07%+32.20%+46.97%

Financials

2023 2024
Net sales 5.45 4.76 4.39 4.05 7.63 524.55 7.8 52.5 20.65 256.91 20.46 20.01 884.39 191.59 167.43 154.5 142.41 268.42 18.45T 274.37 1.85T 726.33 9.04T 719.51 703.73 31.11T
Net income -33Cr -28Cr -26Cr -24Cr -46Cr -3.13TCr -47Cr -313.36Cr -123.25Cr -1.53TCr -122.09Cr -119.41Cr -5.28TCr -26Cr -23Cr -21Cr -19Cr -36Cr -2.49TCr -37Cr -248.8Cr -98Cr -1.22TCr -97Cr -95Cr -4.19TCr
Net Debt -66Cr -57Cr -53Cr -49Cr -92Cr -6.31TCr -94Cr -631.84Cr -248.52Cr -3.09TCr -246.18Cr -240.78Cr -11TCr -45Cr -40Cr -37Cr -34Cr -64Cr -4.37TCr -65Cr -437.6Cr -172.12Cr -2.14TCr -170.5Cr -166.76Cr -7.37TCr
Logo SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Employees
368
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SWTX Stock